Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Michaela Mattheus"'
Autor:
Abhinav Sharma, Silvio E. Inzucchi, Jeffrey M. Testani, Anne Pernille Ofstad, David Fitchett, Michaela Mattheus, Subodh Verma, Faiez Zannad, Christoph Wanner, Bettina J. Kraus
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 737-747 (2024)
Abstract Aims This study aimed to evaluate the bidirectional relationship between kidney and cardiovascular (CV) events in trial participants with type 2 diabetes and CV disease. Methods and results Post hoc analyses of EMPA‐REG OUTCOME using Cox r
Externí odkaz:
https://doaj.org/article/d6eba344c35f43a9afd5fa5b83bba977
Autor:
Samy Hadjadj, Mark E. Cooper, Dominik Steubl, Michaela Petrini, Stefan Hantel, Michaela Mattheus, Christoph Wanner, Merlin C. Thomas
Publikováno v:
Kidney Medicine, Vol 6, Iss 3, Pp 100783- (2024)
Rationale & Objective: Kidney function progressively declines in most patients with type 2 diabetes (T2DM). Many develop progressive chronic kidney disease (CKD), but some experience a more rapid decline, with a greater risk of kidney failure and car
Externí odkaz:
https://doaj.org/article/fe84595be623466a838d50e780663ffe
Autor:
Subodh Verma, Andrew Kosmopoulos, Deepak L. Bhatt, David Fitchett, Anne Pernille Ofstad, Christoph Wanner, Michaela Mattheus, Bernard Zinman, Patrick R. Lawler, Lawrence A. Leiter
Publikováno v:
American Journal of Preventive Cardiology, Vol 15, Iss , Pp 100510- (2023)
Objectives: REDUCE-IT showed that icosapent ethyl (IPE) improved cardiovascular (CV) outcomes in participants with established CV disease (CVD) or type 2 diabetes (T2D) and at least one additional risk factor plus mild-moderate hypertriglyceridemia a
Externí odkaz:
https://doaj.org/article/d083c1a8463845e48238f05fb086aa8d
Autor:
Subodh Verma, Lawrence A. Leiter, Bernard Zinman, Abhinav Sharma, Michaela Mattheus, David Fitchett, Jyothis George, Anne Pernille Ofstad, Mikhail N. Kosiborod, Christoph Wanner, Silvio E. Inzucchi
Publikováno v:
ESC Heart Failure, Vol 8, Iss 4, Pp 2603-2607 (2021)
Abstract Aims In the EMPA‐REG OUTCOME trial, in patients with type 2 diabetes and established atherosclerotic cardiovascular (CV) disease, empagliflozin vs. placebo reduced the risk of hospitalization for heart failure (HHF) by 35%, CV death/HHF by
Externí odkaz:
https://doaj.org/article/35bbcdb9f370489588adedc3953e2157
Autor:
Piero Ruggenenti, Bettina J. Kraus, Silvio E. Inzucchi, Bernard Zinman, Stefan Hantel, Michaela Mattheus, Maximilian von Eynatten, Giuseppe Remuzzi, Audrey Koitka-Weber, Christoph Wanner
Publikováno v:
EClinicalMedicine, Vol 43, Iss , Pp 101240- (2022)
Summary: Background: Diabetic kidney disease with nephrotic-range proteinuria (NRP) is commonly associated with rapid kidney function loss, increased cardiovascular risk, and premature mortality. We explored the effect of empagliflozin in patients wi
Externí odkaz:
https://doaj.org/article/fbb8fa2282594204a573a3a18cd51d49
Autor:
Simke W. Waijer, Di Xie, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus, Maximillian von Eynatten, Lesley A. Inker, Christoph Wanner, Hiddo J. L. Heerspink
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 18 (2020)
Background Early reduction in albuminuria with an SGLT2 (sodium‐glucose cotransporter 2) inhibitor may be a positive indicator of long‐term cardiovascular and renal benefits. We assessed changes in albuminuria during the first 12 weeks of treatme
Externí odkaz:
https://doaj.org/article/b9b63f4483434509a980385e54779671
Autor:
Julio Rosenstock, Vlado Perkovic, John H. Alexander, Mark E. Cooper, Nikolaus Marx, Michael J. Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra, Egon Pfarr, Michaela Mattheus, Uli C. Broedl, Hans-Juergen Woerle, Jyothis T. George, Maximilian von Eynatten, Darren K. McGuire, CARMELINA® investigators
Publikováno v:
Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-15 (2018)
Abstract Background Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA® trial aims to evaluat
Externí odkaz:
https://doaj.org/article/4f753d01958c432990f07fa12eea7bb6
Autor:
Geert Jan Biessels, Jolien Janssen, Esther van den Berg, Bernard Zinman, Mark A. Espeland, Michaela Mattheus, Odd Erik Johansen, on behalf of the CAROLINA® investigators
Publikováno v:
BMC Neurology, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background Type 2 diabetes mellitus is associated with cognitive dysfunction and an increased risk of dementia. Linagliptin is a glucose-lowering agent of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class that is of particular interest fo
Externí odkaz:
https://doaj.org/article/cec3f4073ada4aab9be5a3f9c29f8d8c
Publikováno v:
International Journal of Hypertension, Vol 2013 (2013)
Objective. Report of prespecified and post hoc subgroup analyses of a randomized, controlled trial comparing telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) combination therapy with T80 monotherapy, according to the presence of cardiovascular d
Externí odkaz:
https://doaj.org/article/756da68732774cb59a0065b98fbf0723
Autor:
Moahad S. Dar, Christoph Wanner, Nikolaus Marx, Anne Pernille Ofstad, Michaela Mattheus, Stefan Kaspers, Sami A. Bég
Publikováno v:
Diabetes, Obesity and Metabolism. 25:1372-1384